PsyArXiv
October 9, 2026
Oleksandr Avramchuk, Olha Germanovych, Olha Ivanenko et al.
preprint
Background: Children living in conflict zones experience high levels of psychological distress. Schools can provide an accessible setting for support, yet evidence on the effectiveness of school-based interventions in active war contexts remains limited. Objectives: To evaluate children’s well-being and internal coping resources during the war in Ukraine and to examine the feasibility of a...
Surgical Neurology International
October 9, 2026
Andrea Garcia-Bitar, Eduardo Jesus Castañeda, José Rafael Buenrostro-Rangel et al.
Background: Neurosurgical patients carry a high and frequently undertreated burden of psychological suffering, acute and chronic pain, and neurological deficits amenable to recovery. The resurgence of psychedelic research has produced relevant evidence in adjacent fields, but its applicability to neurosurgery has not been systematized. This review synthesizes that evidence across prevention,...
Psychological trauma : theory, research, practice and policy
October 8, 2026
Hilit Erel-Brodsky, Orit Taubman-Ben-Ari
This study examines dreaming in the context of prolonged collective trauma. Specifically, it investigates whether exposure to the October 7, 2023, Hamas attacks in Israel, characteristics of dream life, and levels of self-compassion are associated with posttraumatic stress symptoms (PTSS) during the ongoing Israel-Hamas war. Participants were 203 Israeli adults (79% women; age range = 21-79...
Progress in neuro-psychopharmacology & biological psychiatry
October 6, 2026
Chad Collyer, Gia Han Le, Maryam Hassan et al.
Short-acting tryptamine psychedelics are emerging as candidate psychiatric therapeutics with pharmacological profiles that may offer practical advantages over longer-acting psychedelics. N,N-dimethyltryptamine (N,N-DMT) and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) differ in pharmacokinetic, receptor, and phenomenological properties, while zalsupindole is a putatively non-hallucinogenic...
Frontiers in Psychiatry
October 5, 2026
Andreas Paris, Foteini Thoma, Aikaterini Velentza et al.
Recent advances in psychedelic research have renewed interest in the potential therapeutic role of psychedelic-assisted interventions in psychiatry. Early clinical trials suggest that compounds such as psilocybin and MDMA, administered within structured therapeutic frameworks, may produce rapid symptom improvements for conditions including depression, post-traumatic stress disorder, and...
Chronic Stress
October 1, 2026
Alan K. Davis, Nathan D. Sepeda, Stacey B. Armstrong et al.
Background/Objectives Retrospective survey and clinical chart review studies have demonstrated the real-world effectiveness of ibogaine and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in addressing a range of mental health challenges among military Veterans in the United States (US), but no prospective research study has examined safety and effectiveness in this population. Design/Methods We...
Current Psychology
October 1, 2026
Mary-Anne Kate, Benjamin Dixon, David L. Hegarty et al.
Abstract: This study examined the relationship between depression and dissociation by assessing how specific dissociative symptoms vary with depression severity in a large Australian clinical sample. A total of 5,384 adults receiving mental health care completed the Depression Anxiety Stress Scales-21 (DASS-21) and the Multidimensional Inventory of Dissociation-60 (MID-60). Analyses included...
JAMA Network Open
October 1, 2026
Kim Madden, Breanne Flood, Imad Kashir et al.
Psilocybin has received increased attention as a potential therapeutic intervention, but it is unclear whether news media reporting reflects the strengths and limitations of the clinical trial evidence. To describe the annual counts of published clinical trials of therapeutic psilocybin and contemporaneous media articles and compare tone, efficacy, and safety messaging. This systematic review...
Psychedelics
October 1, 2026
Diego Borbón
In April 2025, New Mexico enacted the Medical Psilocybin Act, establishing the first legislated statewide medical psilocybin program and becoming the third state to authorize supervised psilocybin use. The Act directs the New Mexico Department of Health to build a regulated system where licensed clinicians provide psilocybin to qualified patients in approved settings for treatment-resistant...
Frontiers in Psychiatry
October 1, 2026
Matthew M. Kinney, Zackary L. Bowers
Ketamine has progressed from solely being an anesthetic agent to a drug of rising clinical and research interest due to its distinctive pharmacological properties. Its dissociative properties and rapid-acting antidepressant effects have made it a prominent area of investigation across many medical and psychiatric applications. This systematic review examines ketamine’s history, mechanisms of...